BRIEF published on 11/14/2024 at 07:35, 7 days 5 hours ago PharmaSGP Sees Strong Revenue Growth in 9M 2024, Raises Full-Year Forecast Revenue Growth Market Strategy 2024 Forecast PharmaSGP OTC Pharmaceuticals
PRESS RELEASE published on 11/14/2024 at 07:30, 7 days 5 hours ago PharmaSGP with strong revenues growth in 9M 2024 – revenues forecast for FY 2024 raised PharmaSGP Holding SE reports strong revenue growth in 9 months of 2024, with preliminary figures showing a 17.0% increase compared to the same period last year. FY 2024 revenue forecast raised Financial Results Revenue Growth Pharmaceuticals Forecast PharmaSGP
BRIEF published on 11/05/2024 at 10:12, 16 days 3 hours ago Leadership Transition at PharmaSGP Holding SE: Peter Gerckens to Succeed Natalie Weigand as CEO Company Growth OTC Pharmaceuticals Peter Gerckens Natalie Weigand PharmaSGP Leadership Change
PRESS RELEASE published on 11/05/2024 at 10:07, 16 days 3 hours ago CEO change at PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as of January 1, 2025 PharmaSGP Holding SE announces CEO change with Peter Gerckens succeeding Natalie Weigand on January 1, 2025. Smooth transition planned for internal succession Succession Plan CEO Change PharmaSGP Holding SE Peter Gerckens Natalie Weigand
BRIEF published on 11/05/2024 at 10:07, 16 days 3 hours ago Leadership Change at PharmaSGP Holding SE: Peter Gerckens Appointed CEO Leadership Transition CEO Change PharmaSGP Holding SE Peter Gerckens Natalie Weigand
PRESS RELEASE published on 11/05/2024 at 10:02, 16 days 3 hours ago EQS-Adhoc: PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer PharmaSGP Holding SE appoints Peter Gerckens as new CEO, succeeding Natalie Weigand. Gerckens, currently CCO, will assume the CEO position on January 1, 2025 Supervisory Board PharmaSGP Holding SE CEO Succession Peter Gerckens Natalie Weigand
BRIEF published on 10/01/2024 at 08:20, 1 month 20 days ago PharmaSGP Holding SE Acquires 477,701 Shares Through Repurchase Offer Share Buyback Treasury Shares Capital Reduction PharmaSGP Repurchase Offer
PRESS RELEASE published on 10/01/2024 at 08:15, 1 month 20 days ago PharmaSGP Holding SE has purchased 477,701 own shares through its public share repurchase offer PharmaSGP Holding SE has purchased 477,701 own shares through public share repurchase offer. The company's acceptance ratio is approximately 80.37% Share Buyback Treasury Shares Public Offer PharmaSGP Holding Acceptance Ratio
BRIEF published on 09/12/2024 at 08:20, 2 months 9 days ago PharmaSGP Continues Dynamic Growth Path in First Half of 2024 Revenue Growth International Expansion PharmaSGP OTC Pharmaceuticals 2024 Financials
BRIEF published on 09/12/2024 at 08:15, 2 months 9 days ago PharmaSGP Holding SE Announces Share Repurchase Program Share Repurchase Acceptance Period PharmaSGP Holding SE 594,405 Shares EUR 21.45
Published on 11/21/2024 at 13:00, 27 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 27 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 27 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 13:00, 27 minutes ago Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Published on 11/21/2024 at 13:00, 27 minutes ago Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension
Published on 11/21/2024 at 12:35, 52 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 12 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 6 hours 29 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 7 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 19 hours 42 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 19 hours 42 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 5 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
